Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The trial is a randomized, open‐label phase III study comparing CPX‐351 vs conventional intensive induction and consolidation chemotherapy in patients with newly diagnosed AML and intermediate‐ or adverse‐risk genetics (according to 2017 ELN criteria), including AML with myelodysplasia‐related changes (AML‐MRC) and therapy‐related AML according to the World Health Organization (WHO) classification. Overall survival (OS) in the restricted set of de novo patients will be the primary endpoint.
Epistemonikos ID: 17adac4a7b0b866448120a830a5ee1a3caf549d8
First added on: May 22, 2024